Brown

0776

Diamond Shamrock

March 10, 1976

Diamond Shamrock
Health Sciences, Inc.
REFERENCE LABORATORY DIVISIO
3728B Olentangy River Road
Columbus, Ohio 43214
614/459-1600
TWX 810/256-2907

J. M. Brown Jr.
Radioisotope Licensing Branch
Division of Fuel Cycle
and National Safety
Nuclear Regulatory Commission
Washington, D.C. 20555

Dear Mr. Brown:

Thank you for your correspondence of mid-January and my apologies for the extended delay in response. At that time, the corporation underwent major corporate changes which had a direct influence on the license application and I delayed resubmission pending definition of its outcome. The situation appears to be currently stabilized.

Diamond Shamrock Health Sciences, of which this Reference Laboratory Division is a part, was a wholly owned subsidiary, and, now has been absorbed by the parent corporation. The former V.P. in charge was terminated and new corporate officers assigned- A. Ford, President and J. Burgoon, V. President. A new Administrative General Manager has been assigned this Division (no technical qualifications), and, for the present, I will continue as Laboratory Director. This facility, in addition, has been moved from the Powell, Ohio location to one in the Columbus, Ohio area. This relocation has provided the advantage of restructuring isolation areas with greater radiation safety, and, in addition, has necessitated a rescheduling of laboratory activities, which will significantly reduce anticipated isotope needs. Animal studies, secretory and metabolic clearance rate studies have been eliminated from the program. These changes are reflected in the new 313-form enclosed.

The new AEC-313 will also reflect answers to the questions in your most recent correspondence. Details of sealed sources are reflected in addendum B; supplementary information on RPO, K. Keplinger are continued in addendum A; survey meter information is seen in addendum C; and, a schematic of our new laboratory facility is provided in addendum D. I would bring to your attention laboratory improvements within this facility. An isolated, restricted and lead-lined area to be used as a "hot-lab" for handling and storage of all licensable quantities of ^{3}H, ^{14}C, and ^{125}I. An area which was not available in the SDI facility. Under these conditions, only micro-quantities of radio activity need to be used in the general, but restricted, lab areas. Access to this general restricted area will still be controlled via electronic-lock devices with access limited to lab personnel. In addition, hot waste will be stored in a lead-lined area for commercial disposal, and

N/2

hood facilities have been expanded some 300% compared to the former SDI facility.

Finally, the radioisotope committee will be constituted of:

L. Gaudette, Lab Director
K. Keplinger, RPO
N. Chinh, General Supervisor
A. Gaudette, General Supervisor
E. Mazzaferri, M.D., Medical Consultant, Chief Endocrinology, O.S.U.

The RIC is scheduled to meet monthly.

Personnel will be monitored wearing badges and rings. Pocket dosimeters for the present time are no longer under consideration as being inadequate for our needs. Survey of badges and rings will employ the commercial services of Searle Analytic, Inc. Bioassay (urine and thyroid scans) are to be set up along the guide lines established by Mr. Charles Kilian of the New England Nuclear Corporation. Mr. Keplinger is presently setting these systems to be operative within 4-6 weeks. It is anticipated that urine and thyroid bioassay will be set up weekly-urine being quantitated by liquid scintillation measurements and scans and employing instrumentation recommended by Mr. Kilian.

I sincerely hope the details incorporated herein will provide you the necessary information relative to processing our application. Thank you.

Sincerely yours,

Leo E. Gaudette

Leo E. Gaudette, Ph.D.
Laboratory Director

LEG:cv